<DOC>
	<DOC>NCT01068262</DOC>
	<brief_summary>This study will test the weighted average inhibition of u-NTx/Cre (aminoterminal crosslinked telopeptide of Type 1 collagen) and AUC (0-168 hours) of Odanacatib</brief_summary>
	<brief_title>Safety and Tolerability of Odanacatib (0822-059)</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>male subject between the ages of 50 and 75 years; post menopausal female subjects between the ages of 45 and 75 years Subject is in good general health Subject has no evidence of metabolic bone disorder other than osteopenia or osteoporosis Subject is a nonsmoker Subject works night shift and is unable to avoid nightshift work during the study Subject has had major surgery, donated blood or participated in another investigational study with in the past 4 weeks Subject has a history of stroke, chronic seizures, or major neurological disease Subject has a history of cancer Subject consumes excessive amounts of alcohol or caffeine</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>